Atrix Laboratories Inc has submitted its eighth Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) for approval of a generic formulation of a topical dermatology product.

David R. Bethune, chairman and chief executive officer said, "We started this dermatology business as a revenue generating opportunity for Atrix. We remain committed to submitting a number of filings each year for the next several years and look forward to updating our shareholders on this important business."

Atrix Laboratories is an emerging specialty pharmaceutical company focused on advanced drug delivery. With five unique patented technologies, Atrix is currently developing a diverse portfolio of proprietary products, including oncology, pain management, and dermatology products. The company also partners with large pharmaceutical and biotechnology companies to apply its proprietary technologies to new chemical entities or to extend the patent life of existing products.